A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Clemons, M
  • Stober, C
  • Mates, M
  • Joy, AA
  • Robinson, A
  • Hilton, J
  • Blanchette, P
  • Aseyev, O
  • Pond, Gregory
  • Fergusson, D

publication date

  • May 1, 2019